Live event scheduled for Friday, February 24th at 11:00 am Eastern TimeIRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON...
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board DirectorBURLINGTON, Mass. and JERUSALEM, Feb....
IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused...
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA®,...
Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain StimulationBURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023...
CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize...
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant.NEW YORK, Jan. 25, 2023 (GLOBE...
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,...
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused...
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader...
-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023...
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxietyMALVERN, Pa., Jan. 17, 2023 (GLOBE...
VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0)...
EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA, Jan. 16, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD),...
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at...